Sponsors (62)
The bill trades faster, broader legal tools and clearer definitions to deter and prosecute fentanyl-related substances and to allow some research continuity, against expanded criminal exposure, tighter research constraints and administrative/compliance burdens that may raise costs and limit access for researchers, providers, and some patients.
Law enforcement, prosecutors, and courts gain a clear, consistent statutory definition and immediate authority to identify, charge, and disrupt fentanyl-related substances, enabling faster seizures and prosecutions.
Members of the public (communities at risk of overdose) are likely to face fewer novel fentanyl analogs on the street because the law treats broad classes of fentanyl-related substances as illegal, which should help reduce accidental overdoses and improve public safety.
Researchers, hospitals, and research staff get streamlined administrative pathways (single institutional registrations, shared-authority, 30–90 day continuation windows, limited incidental manufacturing, and electronic notification) that speed initiation and continuation of Schedule I research.
Researchers, clinicians, and some patients face increased barriers because broad, class-wide Schedule I placement raises administrative burdens on research and could delay or restrict study of potentially therapeutic fentanyl-related compounds.
People potentially exposed to criminal laws—and taxpayers—face expanded criminal exposure and risk of harsher penalties because broader definitions and immediate application can increase prosecutions, possibly enlarging incarceration rates and associated public costs.
Businesses, research institutions, and taxpayers may incur higher compliance and enforcement costs because faster implementation, broader prohibitions, and expanded permitted in‑lab manufacturing raise regulatory complexity and resource needs.
Based on analysis of 7 sections of legislative text.
Creates a class-wide Schedule I definition for fentanyl-related substances and establishes expedited DEA research registration and rulemaking requirements.
Creates a class-wide Schedule I control for "fentanyl-related substances," making any compound that fits the statute's structural definition presumptively Schedule I unless specifically exempted or already scheduled elsewhere. It also revises DEA research registration procedures to allow expedited and shared registrations for certain Schedule I research, requires DOJ/DEA rulemaking and reporting, updates statutory cross-references, and adds a definition of “fentanyl-related substance” to the general definitions. The bill requires the Attorney General to issue implementation rules (including interim final rules) within six months, makes the statutory changes effective on enactment, and preserves certain procedural protections for research while expanding criminal exposure for possession, manufacture, and distribution of substances that meet the new class definition.
Official title: To amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.
Introduced January 3, 2025 by H. Morgan Griffith · Last progress February 10, 2025